CyclopharmASX:CYC 46 FCF Margin % is -6,743.35% as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 116 Medical Distribution companies, Cyclopharm ranks worse than 97.41% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cyclopharm's Free Cash Flow for the
six
months ended in Dec. 2025 was A$-11.67 Mil. Cyclopharm's Revenue for the
six
months ended in Dec. 2025 was A$0.17 Mil. Therefore, Cyclopharm's FCF Margin % for the quarter that ended in Dec. 2025 was -6,743.35%.
The historical rank and industry rank for Cyclopharm's FCF Margin % or its related term are showing as below:
ASX:CYC'
s FCF Margin % Range Over the Past 10 Years
Min: -116.45 Med: -22.51 Max: -6.86
Current: -116.44
During the past 13 years, the highest FCF Margin % of Cyclopharm was -6.86%. The lowest was -116.45%. And the median was -22.51%.
ASX:CYC's FCF Margin % is ranked worse than 97.41% of 116
companies
in the Medical Distribution industry
Industry Median: 1.06
vs ASX:CYC: -116.44
Cyclopharm FCF Margin % Related Terms
Cyclopharm FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cyclopharm's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cyclopharm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm FCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cyclopharm's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a FCF Margin % of -6,743.35% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cyclopharm and its competitors. According to the industry distribution chart, Cyclopharm ranks #113 out of 116 companies in the Medical Distribution industry, placing it in the top 97.4%.
Is Cyclopharm's FCF Margin % too high?
Cyclopharm's current FCF Margin % is -6,743.35%. Based on the distribution chart, Cyclopharm ranks #113 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's FCF Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #113 out of 116 companies for FCF Margin %. This places Cyclopharm in the lower half of its industry. The industry median FCF Margin % is 1.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Distribution company?
The median FCF Margin % among Medical Distribution companies is 1.06, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median FCF Margin % is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current FCF Margin % is -6,743.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current FCF Margin % is -6,743.35%. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current FCF Margin % is -6,743.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
FCF Margin %: -6,743.35%
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
